NASDAQ
WHWK
Last Price
US $3.81
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Whitehawk Therapeutics Inc carries no debt; cash flow comfortably covers obligations.
Financial risk - Healthy cash flow growth.
Whitehawk Therapeutics Inc's free cash flow has decreased 60.10% from $-61.20M last year to $-97.98M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Whitehawk Therapeutics Inc's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Whitehawk Therapeutics Inc's debt has decreased relative to shareholder equity from 0.02 last year to 0.00 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
Whitehawk Therapeutics Inc has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Whitehawk Therapeutics Inc earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
Whitehawk Therapeutics Inc's profit margin has increased (-100.00%) in the last year from -245.13% to 0.00%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Whitehawk Therapeutics Inc's short-term assets of $149.01M exceed its short-term liabilities of $14.52M
Decreasing performance - ROA.
Whitehawk Therapeutics Inc's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Whitehawk Therapeutics Inc's return on equity of -79.63%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Whitehawk Therapeutics Inc's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Whitehawk Therapeutics Inc had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Whitehawk Therapeutics Inc has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Whitehawk Therapeutics Inc has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Whitehawk Therapeutics Inc's yearly earnings has increased -67.66% since last year from $-63.69M to $-20.60M, signaling increasing performance
Decreasing performance - Healthy revenue growth.
Whitehawk Therapeutics Inc's yearly revenue has decreased -72.50% since last year from $25.98M to $7.14M, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -105.62% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Whitehawk Therapeutics Inc's 3-year revenue CAGR of -22.27% is negative, indicating declining revenue over the past 3 years
Increasing performance - Revenue consistency.
Whitehawk Therapeutics Inc had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Whitehawk Therapeutics Inc had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Whitehawk Therapeutics Inc has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Whitehawk Therapeutics Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Whitehawk Therapeutics Inc is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Whitehawk Therapeutics Inc has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Whitehawk Therapeutics Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Whitehawk Therapeutics Inc has a price-to-book ratio of 2.27x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Whitehawk Therapeutics Inc has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-79.63%
Return on equity
ROIC: -105.62%
Valuation History
-2.4X
Price to Earnings
EV/EBITDA: -1.4X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $3.81
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.